期刊文献+

降同型半胱氨酸疗法对经皮冠状动脉介入治疗术后患者不良心血管事件的影响 被引量:9

下载PDF
导出
摘要 目的:探讨降同型半胱氨酸(Hcy)疗法对经皮冠状动脉介入治疗(PCI)术后不良心血管(MACE)事件发生率的影响。方法:纳入2010年9月至2012年8月期间在我院心内科住院确诊冠心病并行PCI术的患者228例,随机分为对照组(120例)和降Hcy组(108例)。对照组只接受基本用药,降Hcy组除基本用药外,每天加服1mg叶酸、10mg维生素B6和400mg维生素B12。比较术后即刻、术后6、12个月两组患者的叶酸、维生素B6、维生素B12和Hcy水平以及术后1、6和12个月MACE事件的发生情况。结果:术后6个月,降Hcy组的叶酸和维生素B12水平均较对照组显著升高;术后12个月,降Hcy组的叶酸、维生素B6和维生素B12水平均较对照组显著升高,Hcy水平较对照组显著降低。术后6个月和术后12个月,降Hcy组的MACE事件发生率均较对照组低,其中,降Hcy组在术后6个月的心绞痛复发率和再次血运重建率均较对照组低;降Hcy组在术后12个月的心绞痛复发率、非致死性心肌梗死发生率和再次血运重建率均较对照组低。结论:PCI术后患者进行降Hcy的干预可减少术后MACE事件的发生率。
出处 《实用医学杂志》 CAS 北大核心 2013年第5期769-771,共3页 The Journal of Practical Medicine
基金 广东省医学科研基金资助项目(编号:B2011310 A2012663) 佛山市顺德区医学科研项目基金资助项目(编号:2011002)
  • 相关文献

参考文献9

  • 1陈玉映,胡允兆,陈盈文,何宗云,郑素琳,吴焱贤.血清Hcy、sCD40L及LDL-C与冠状动脉支架内再狭窄的相关性研究[J].新医学,2012,43(1):10-13. 被引量:11
  • 2刘学波,王克强,葛均波.细胞迁移机制在冠状动脉支架再狭窄作用的研究进展[J].心血管病学进展,2004,25(6):436-439. 被引量:8
  • 3De Luca G, Suryapranata H, Gregorio G, et al. Homocysteine and its effects on in-stent restenosis [J]. Circulation, 2005, 112 (19) : e307-e311.
  • 4黄群英,张高寅,刘卫华,黄晓明,庞振瑶.早发冠心病危险因素与冠状动脉病变的关系[J].广东医学,2012,33(3):374-376. 被引量:11
  • 5Kojoglanian S A, Jorgensen M B, Wolde-Tsadik G, et al. Restenosis in intervened coronaries with hyperhomocysteinemia (RICH) [J]. Am Heart J, 2003,146(6) : 1077-1081.
  • 6Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial [J]. JAMA, 2002,288(8) :973-979.
  • 7Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting [J]. N Engl J Med, 2004,350(26) : 2673-2681.
  • 8van Hattum E S, Doevendans P A, Moll F L. Does folate therapy reduce the risk of coronary restenosis [J]? Neth Heart J, 2007,15(1) : 12-15.
  • 9Weiss N, Heydrick S J, Postea O, et al. Influence of hyperhomocysteinemia on the cellular redox state--impact on homocysteine-induced endothelial dysfunction [J]. Clin Chem Lab Med, 2003,41 ( 11 ) : 1455-1461.

二级参考文献61

  • 1蒋晖,李锦,毛建斌,陈茂,范忠才,黄德嘉.同型半胱氨酸对内皮细胞CD40表达的影响[J].心脏杂志,2004,16(5):431-434. 被引量:11
  • 2刘学波,王克强,葛均波.细胞迁移机制在冠状动脉支架再狭窄作用的研究进展[J].心血管病学进展,2004,25(6):436-439. 被引量:8
  • 3ANGULO P. Nonalcoholic fatty liver disease [ J ]. N Engl J Med, 2002, 346 (16) : 1221-1231.
  • 4JAKUBOWSKI H. The determination of homocysteine- thiolactone in biological samples [ J ]. Anal Biochem, 2002, 308 (1): 112-119.
  • 5LIEVENS D, EIJGELAAR ,W J, BIESSEN E A, et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis [ J ]. Thromb Haemost, 2009, 102 (2) : 206-214.
  • 6TURKER S, GUNERI S, AKDWNIZ B, et al. Useful- ness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in pa- tients with stable coronary artery disease [ J ]. Am J Car- diol, 2006, 97 (2): 198-202.
  • 7TEWARI S,KUMAR S,KAPOOR A,et al.Premature coronaryartery disease in North India:an angiography study of 1971 pa-tients[J].Indian Heart J,2005,57(4):311-318.
  • 8CHOE J Y,PARK S H,KIM S K.Serum cystatin C is a potentialendogenous marker for the estimation of renal function in male goutpatients with renal impairment[J].J Korean Med Sci,2010,25(1):42-48.
  • 9ARPEGARD J,OSTERGREN J,DE FAIRE U,et al.Cystatin-C——a marker of peripheral atherosclerotic disease?[J].Ather-osclerosis,2008,199(2):397-401.
  • 10KOENIG W,TWARDELLA D,BRENNER H,et al.Plasma concen-trations of cystatin C in patients with coronary heart disease and riskfor secondary cardiovascular events:more than simply a marker of glo-merular filtration rate[J].Clin Chem,2005,51(2):321-327.

共引文献22

同被引文献99

  • 1梁伟,吴春芳,杨晖,余强,张大东,陆国平.不同调脂方案对冠心病患者ICAM-1、VCAM-1和MCP-1的影响[J].上海交通大学学报(医学版),2011,31(2):208-211. 被引量:6
  • 2范连慧,刘龙,吴晓倩,曹志强,向军.肾移植前后血浆同型半胱氨酸浓度升高与心血管病变相关[J].中华器官移植杂志,2006,27(8):506-507. 被引量:3
  • 3康维强,宋达琳,郭新贵,李梅,滕金龙,任国瑞.急性冠状动脉综合征患者血管因子与冠状动脉斑块特征的相关性研究[J].中华心血管病杂志,2007,35(11):1020-1023. 被引量:21
  • 4Watorek E, Szymczak M, Boratynska M, et al. Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors [ J ].Transplant Proc, 2011, 43 (8): 2967-2969.
  • 5Weir MR, Burgess ED, Cooper JE, et al. Assessment and management of hypertension in transplant patients [ J]. J Am Soe Nephrol, 2015 [ Epub ahead of print].
  • 6McCaughan JA, Courtney AE. The clinical course of kidney transplant recipients after 20 years of graft function[J]. Am J Transplant, 2015, 15 (3) : 734- 740.
  • 7Janda K, Aksamit D, Drozdz M, et al. Influence of elevated homocystein level and selected lipid parameters in kidney transplant patients on the progression of atherosclerotic changes assessed by intima-media thickness index (CCA-IMT) [ J ]. 波兰文),2012,69(9):670-674.
  • 8Tan H, Shi C, Jiang X, et al. Hyperhomocysteinemia promotes vascular remodeling in vein graph in mice [ J ]. Front Biosci, 2014, 19: 958-966.
  • 9Welch GN, Loscalzo J. Homocysteine and atherothrombosis[J]. N Engl J Med, 1998, 338 (15) : 1042-1050.
  • 10Marcucci R, Zanazzi M, Bertoni E, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomoeysteinemie renal-transplant recipients [ J]. Transplantation, 2003, 75 (9): 1551-1555.

引证文献9

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部